AR075982A1 - Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion - Google Patents
Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicionInfo
- Publication number
- AR075982A1 AR075982A1 ARP100101008A ARP100101008A AR075982A1 AR 075982 A1 AR075982 A1 AR 075982A1 AR P100101008 A ARP100101008 A AR P100101008A AR P100101008 A ARP100101008 A AR P100101008A AR 075982 A1 AR075982 A1 AR 075982A1
- Authority
- AR
- Argentina
- Prior art keywords
- human
- csf
- antibody
- afucosilated
- cytokins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/202—IL-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
Abstract
Reivindicacion 1: El uso de un anticuerpo afucosilado que se fija específicamente a un antígeno tumoral con una cantidad de fucosa de 60% o menos, para la fabricacion de un medicamento para el tratamiento de cáncer en combinacion con una o más citoquinas seleccionadas del grupo de GM-CSF humano, M-CSF humano y IL-3 humano.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09004754 | 2009-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR075982A1 true AR075982A1 (es) | 2011-05-11 |
Family
ID=41112813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101008A AR075982A1 (es) | 2009-03-31 | 2010-03-29 | Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion |
Country Status (9)
Country | Link |
---|---|
US (1) | US20100247484A1 (es) |
EP (1) | EP2413966A1 (es) |
JP (1) | JP2012521379A (es) |
CN (1) | CN102355909A (es) |
AR (1) | AR075982A1 (es) |
CA (1) | CA2754807A1 (es) |
SG (1) | SG174962A1 (es) |
TW (1) | TW201038285A (es) |
WO (1) | WO2010115554A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1692182B1 (en) | 2003-11-05 | 2010-04-07 | Roche Glycart AG | Cd20 antibodies with increased fc receptor binding affinity and effector function |
RU2013131444A (ru) * | 2010-12-16 | 2015-01-27 | Рош Гликарт Аг | Сочетанная терапия афукозилированным антителом к cd20 и ингибитором mdm2 |
JP2014515753A (ja) | 2011-04-21 | 2014-07-03 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 新規な結合剤−薬物複合体(adc)およびそれらの使用 |
JP2014520784A (ja) | 2011-07-06 | 2014-08-25 | モルフォシス・アー・ゲー | 抗cd20抗体と抗gm−csf抗体との治療的組合せおよびその使用 |
WO2013127465A1 (en) * | 2012-03-02 | 2013-09-06 | Roche Glycart Ag | Predicitive biomarker for cancer treatment with adcc enhanced antibodies |
WO2014114595A1 (en) | 2013-01-23 | 2014-07-31 | Roche Glycart Ag | Predictive biomarker for cancer treatment with adcc-enhanced antibodies |
EP3310440A1 (de) | 2015-06-22 | 2018-04-25 | Bayer Pharma Aktiengesellschaft | Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren gruppen |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
RU2018136778A (ru) | 2016-03-24 | 2020-04-24 | Байер Фарма Акциенгезельшафт | Пролекарства цитотоксических лекарственных средств, содержащие ферментативно расщепляемые группы |
WO2017216028A1 (en) | 2016-06-15 | 2017-12-21 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
CN110312533B (zh) | 2016-12-21 | 2023-11-03 | 拜耳公司 | 具有酶促可裂解的基团的细胞毒性活性剂的前药 |
JP7066714B2 (ja) | 2016-12-21 | 2022-05-13 | バイエル・ファルマ・アクティエンゲゼルシャフト | 酵素的に切断可能な基を有する抗体薬物コンジュゲート(adc) |
US11433140B2 (en) | 2016-12-21 | 2022-09-06 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (ADCs) having KSP inhibitors |
CN108823151B (zh) * | 2018-06-26 | 2021-11-16 | 中国人民解放军总医院第五医学中心 | Plekhq1蛋白在制备抑制细胞凋亡的产品中的应用 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
EP0531472B1 (en) | 1991-03-06 | 2003-08-13 | MERCK PATENT GmbH | Humanized monoclonal antibodies |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US6750334B1 (en) | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
SK17282000A3 (sk) | 1998-05-15 | 2002-04-04 | Imclone Systems Incorporated | Nerádioaktívne označený inhibítor proteínového tyrozínkynázového receptora |
DK2270147T4 (da) | 1999-04-09 | 2020-08-31 | Kyowa Kirin Co Ltd | Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
PE20020801A1 (es) | 2001-01-05 | 2002-09-06 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
US7151164B2 (en) * | 2002-02-14 | 2006-12-19 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
KR100988949B1 (ko) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | 당단백질 조성물 |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
ATE357460T1 (de) | 2002-01-18 | 2007-04-15 | Pf Medicament | Antikörper gegen igf-ir und ihre verwendungen |
NZ571508A (en) | 2002-05-24 | 2010-05-28 | Schering Corp | Neutralizing human anti-IGFR antibody |
KR101348472B1 (ko) | 2002-10-17 | 2014-01-07 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
PT1572744E (pt) | 2002-12-16 | 2010-09-07 | Genentech Inc | Variantes de imunoglobulina e utilizações destas |
KR101498588B1 (ko) | 2003-01-22 | 2015-03-05 | 로슈 글리카트 아게 | 융합 구성체와 Fc 수용체 결합 친화도 및 이펙터 기능이 증가된 항체를 생성하기 위한 이의 용도 |
AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
CA2534077A1 (en) | 2003-07-29 | 2005-02-10 | Morphotek Inc. | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
EP1663306A2 (en) | 2003-09-05 | 2006-06-07 | Genentech, Inc. | Antibodies with altered effector functions |
EP1692182B1 (en) * | 2003-11-05 | 2010-04-07 | Roche Glycart AG | Cd20 antibodies with increased fc receptor binding affinity and effector function |
US7259249B2 (en) * | 2003-12-01 | 2007-08-21 | Immunomedics, Inc. | Method for preparing conjugates of proteins and chelating agents |
WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
EP1810035A4 (en) | 2004-11-10 | 2010-03-17 | Macrogenics Inc | EFFECTOR FUNCTION OBTAINED BY CREATION BY BIOLOGICAL GENE OF FC ANTIBODY REGIONS |
PL1871805T3 (pl) | 2005-02-07 | 2020-03-31 | Roche Glycart Ag | Cząsteczki wiążące antygen, które wiążą egfr, wektory kodujące te cząsteczki oraz ich zastosowania |
EP1877441A2 (en) | 2005-04-26 | 2008-01-16 | Bioren, Inc. | Method of producing human igg antibodies with enhanced effector functions |
US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
AU2006290433B2 (en) | 2005-08-26 | 2012-06-07 | Roche Glycart Ag | Modified antigen binding molecules with altered cell signaling activity |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
EP2142569A2 (en) | 2007-03-28 | 2010-01-13 | Biogen Idec, Inc. | Non-fucosylated antibodies |
-
2010
- 2010-03-29 AR ARP100101008A patent/AR075982A1/es unknown
- 2010-03-29 US US12/748,484 patent/US20100247484A1/en not_active Abandoned
- 2010-03-30 CA CA2754807A patent/CA2754807A1/en not_active Abandoned
- 2010-03-30 EP EP10711591A patent/EP2413966A1/en not_active Withdrawn
- 2010-03-30 SG SG2011070646A patent/SG174962A1/en unknown
- 2010-03-30 CN CN2010800125596A patent/CN102355909A/zh active Pending
- 2010-03-30 TW TW099109716A patent/TW201038285A/zh unknown
- 2010-03-30 JP JP2012501195A patent/JP2012521379A/ja active Pending
- 2010-03-30 WO PCT/EP2010/002007 patent/WO2010115554A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2010115554A1 (en) | 2010-10-14 |
US20100247484A1 (en) | 2010-09-30 |
TW201038285A (en) | 2010-11-01 |
CN102355909A (zh) | 2012-02-15 |
EP2413966A1 (en) | 2012-02-08 |
SG174962A1 (en) | 2011-11-28 |
CA2754807A1 (en) | 2010-10-14 |
JP2012521379A (ja) | 2012-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR075982A1 (es) | Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion | |
CY1121882T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
SV2006002143A (es) | Uso de un anticuerpo para el tratamiento del cancer resistente al platino | |
DOP2016000133A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
CO7350624A2 (es) | Inhibidores de la tirosina-quinasa de bruton | |
UY32882A (es) | (heteroarilmetil) tiohidantoínas sustituidas | |
EP4272731A3 (en) | Compositions for the delivery of therapeutic agents and methods of use and making thereof | |
EA201691023A1 (ru) | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством | |
AR096184A1 (es) | Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpos para cd22-fármaco | |
EP3686200A3 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
BR112015022047A8 (pt) | uso de uma composição compreendendo nanopartículas contendo um fármaco da família limo e uma albumina | |
CL2012002326A1 (es) | Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana. | |
NI201200175A (es) | Métodos de tratamiento de cáncer de vejiga | |
MX347893B (es) | Conjugados de farmaco y anticuerpo humano contra factor de tejido. | |
AR074360A1 (es) | Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
AR077866A1 (es) | Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina | |
CL2012003625A1 (es) | Una composicion acuosa que contiene bromhexina, en donde la composicion tiene una cantidad de azucar-alcoholes inferior a 10 g referida a 100 ml de la composicion; y su uso para la terapia secretorica en enfermedades broncopulmonares agudas y cronicas. | |
DOP2010000304A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
WO2015050959A8 (en) | Anti-kit antibodies and methods of use thereof | |
BR112012026707A2 (pt) | uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado | |
BR112015027309A2 (pt) | anticorpo, composição, método de tratamento e uso de um anticorpo | |
CL2011001131A1 (es) | Uso de una formulacion que sirve para preparar un medicamento para una inyeccion, que reduce al minimo la inflamacion en el sitio de la inyeccion de un anticuerpo, y donde la formulacion comprendeun anticuerpo 2h7 y variantes del anticuerpo y polivinilpirrolidona (pvp) | |
AR082693A1 (es) | Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf | |
CL2013003324A1 (es) | Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |